Healthcare Industry News: blood glucose
News Release - December 13, 2010
Medtronic Launches CareLink Pro 3.0, the First Diabetes Management Software to Offer Advanced Decision SupportSoftware Offers Therapy Considerations to Help Healthcare Professionals Make More Informed Treatment Decisions
MINNEAPOLIS--(Healthcare Sales & Marketing Network)-- Medtronic, Inc. today announced the Food and Drug Administration (FDA) approval and the market launch of CareLink® Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes. The software analyzes data from a patient’s insulin pump, continuous glucose monitoring (CGM) device, and blood glucose meter to identify the most important patient information in one easy-to-use dashboard. In addition, the software offers therapy considerations that clinicians can use as a starting point to discuss therapy changes with their patients to help improve glucose control.
“With the new CareLink Pro reports that aggregate data into one place, I will now be able to assess my patients’ glucose control and insulin delivery within minutes. In addition, by using the new therapy considerations, I will be able to spend much less time on data interpretation and more time using this information to discuss diabetes management with my patients,” said Jill Abelseth, M.D., FACE of The Endocrine Group.
The new Therapy Management Dashboard provides a snapshot of the patient’s key insulin delivery and glucose information on one page. In addition, it pinpoints the exact times the patient experienced a low (hypoglycemic) or high (hyperglycemic) glucose pattern and prioritizes these patterns so that clinicians know which times of day are the biggest challenges for their patients.
The new Episode Summary highlights key events that occur prior to hypoglycemic and hyperglycemic episodes, providing clinicians with quick insights on potential areas that may need to be addressed. Furthermore, the Episode Summary offers therapy considerations so that clinicians can make the most informed treatment decisions possible. By reducing the amount of time it takes to interpret patient data, clinicians may have more time to spend with patients fine tuning and making adjustments to therapy and behavior.
“We know diabetes management is complex and that gathering adequate information to make informed treatment decisions can be a challenge for clinicians and patients. Our goal with CareLink Pro 3.0 is to simplify this complexity by integrating patient data, helping providers identify patterns, and offering clinicians therapy considerations,” said Francine R. Kaufman, M.D., Chief Medical Officer and Vice President, Global Medical, Clinical & Health Affairs at Medtronic Diabetes. “We believe decision support is a key advancement toward developing an artificial pancreas, which will rely upon automated decisions to make adjustments to patients’ therapy, and are excited to bring it to the medical community.”
CareLink is an integral part of the MiniMed Paradigm® REAL-Time Revel™ System, which is the only FDA approved integrated system that combines an insulin pump with CGM. The recent STAR 3 trial demonstrated that patients in all age groups (adults, teens, and children) using the Medtronic integrated system achieved a statistically significant reduction in A1C at three months, which was sustained over the course of one year. A1C is a measurement of glucose control over a two-to-three-month period.
About the Diabetes Business at Medtronic
The Diabetes business at Medtronic (www.medtronicdiabetes.com) is the world leader in advanced diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems, and therapy management software, as well as world-class, 24/7 expert consumer and professional service and support.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAustin L. Chiang, M.D., M.P.H. Joins Medtronic As Chief Medical Officer for Gastrointestinal Business
Medtronic Hugo(TM) Robotic-Assisted Surgery System Receives European CE Mark Approval
Medtronic Expands Minimally Invasive Spine Surgery Ecosystem with Next-Generation Spinal Technologies